Advanced search×

Interpenetrating polymer network blend microspheres of chitosan and hydroxyethyl cellulose for controlled release of isoniazid.

Int J Biol Macromol 47(2):171-9 (2010) PMID 20471411

Glutaraldehyde crosslinked interpenetrating polymer network (IPN) blend microspheres of chitosan (CS) and hydroxyethyl cellulose (HEC) were prepared in the form of microspheres (66-82 microm dia) and investigated for the controlled release (CR) of isoniazid (INH), an antituberculosis drug. Microspheres were characterized by X-ray diffraction (XRD) to study the uniform distribution of drug in the matrices, differential scanning calorimetry (DSC) and thermogravimetry (TGA) to study thermal stabilities of IPN blends. Fourier transform infrared (FTIR) spectroscopy was used to understand chemical interactions and to assess the IPN structure. Scanning electron microscopy (SEM) was employed to investigate the morphology of microspheres. Drug-loaded microspheres were produced in spherical shapes with encapsulation efficiency ranging from 50 to 66%. Equilibrium swelling measured in pH 7.4 buffer solution as well as in vitro release of drug in pH 1.2 and 7.4 buffer solutions indicated the dependence of drug release on crosslinking as well as blend composition of the IPN matrix.

Copyright © 2010 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.ijbiomac.2010.05.003
Version: za2963e q8zaf q8zb8 q8zcb q8zd5 q8zee q8zfb q8zg7

Similar articles you may find interesting…

  1. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease.

    Wiley Interdiscip Rev RNA 2(1):35-47 (2010) PMID 20049829

  2. Chitosan as a carrier for targeted delivery of small interfering RNA

    Int J Pharm 399(1-2):11 (2010) PMID 20732398

    The recent discovery of RNA interference (RNAi) technology for gene therapy has triggered extensive research efforts for developing small interfering RNA (siRNA) loaded nanocomplexes of chitosan and its derivatives for silencing genes. Due to its large molecular weight ( approximatel...
  3. Long-term efficacy of pravastatin therapy in diabetic patients undergoing complete coronary revascularization.

    J Atheroscler Thromb 17(4):350-5 (2010) PMID 20154448

    During follow-up (8.8+/-2.6 years), 103 patients died (including 43 who died of cardiac causes). The Multivariate analysis showed statin therapy to be significantly associated with reduced cardiac mortality (HR 0.39, 0.16-0.95; p=0.039), but not with all-cause mortality. CONCLUSION: Statin therapy w...